159 related articles for article (PubMed ID: 23079299)
1. Evidence and values: paying for end-of-life drugs in the British NHS.
Chalkidou K
Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
[TBL] [Abstract][Full Text] [Related]
2. Can the NICE "end-of-life premium" be given a coherent ethical justification?
Cookson R
J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
[TBL] [Abstract][Full Text] [Related]
3. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
4. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
Steinbrook R
N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
[No Abstract] [Full Text] [Related]
5. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
6. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
7. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
8. Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints.
McHugh N; van Exel J; Mason H; Godwin J; Collins M; Donaldson C; Baker R
Soc Sci Med; 2018 Feb; 198():61-69. PubMed ID: 29276987
[TBL] [Abstract][Full Text] [Related]
9. Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access.
Njoroge MW; Walton M; Hodgson R
Value Health; 2024 Jun; 27(6):730-736. PubMed ID: 38447743
[TBL] [Abstract][Full Text] [Related]
10. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
11. Estimating 'costs' for cost-effectiveness analysis.
Miners A
Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
[TBL] [Abstract][Full Text] [Related]
12. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
13. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
14. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
15. 10 Years of End-of-Life Criteria in the United Kingdom.
Bovenberg J; Penton H; Buyukkaramikli N
Value Health; 2021 May; 24(5):691-698. PubMed ID: 33933238
[TBL] [Abstract][Full Text] [Related]
16. NICE's social value judgements about equity in health and health care.
Shah KK; Cookson R; Culyer AJ; Littlejohns P
Health Econ Policy Law; 2013 Apr; 8(2):145-65. PubMed ID: 22717361
[TBL] [Abstract][Full Text] [Related]
17. Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.
Morrell L; Wordsworth S; Fu H; Rees S; Barker R
BMC Health Serv Res; 2017 Aug; 17(1):613. PubMed ID: 28854927
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective public health guidance: asking questions from the decision-maker's viewpoint.
Chalkidou K; Culyer A; Naidoo B; Littlejohns P
Health Econ; 2008 Mar; 17(3):441-8. PubMed ID: 17764094
[TBL] [Abstract][Full Text] [Related]
19. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Devlin N; Parkin D
Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
[TBL] [Abstract][Full Text] [Related]
20. At the center of health care policy making: the use of health technology assessment at NICE.
Stevens AJ; Longson C
Med Decis Making; 2013 Apr; 33(3):320-4. PubMed ID: 23519880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
